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Abstract
Background: Multi-drug resistance (MDR) has been a cause of concern for tuberculosis (TB) control in both
developed and developing countries. This study described the characteristics and risk factors associated with
MDR-TB among 287 cases and 291 controls in Henan province, China.
Methods: A hospital-based case-control study was conducted between June 2012 and December 2013. The
study subjects were selected using multistage probability sampling. Multivariate conditional logistic regression
models were used to determine the risk factors associated with MDR-TB.
Results: The following risk factors for MDR-TB were identified: previous TB treatment (AOR = 4.51, 95 % CI:
3.55–5.56), male sex (AOR = 1.09, 95 % CI: 0.24–1.88), high school or lower education degree (AOR = 1.87,
95 % CI: 1.27–2.69), unemployment (AOR = 1.30, 95 % CI: 0.78–2.52), long distance of residence from the
health facility (AOR = 6.66,95 % CI: 5.92–7.72), smoking (AOR = 2.07, 95 % CI: 1.66–3.19), poor knowledge
regarding MDR-TB (AOR = 2.06, 95 % CI: 1.66–2.92), traveling by foot to reach the health facility (AOR = 1.85,
95 % CI: 1.12–3.09), estimated amount of time to reach the health facility was greater than 3 h (AOR = 1.42,
95 % CI: 0.51–2.35), social stigma (AOR = 1.17, 95 % CI: 0.27–2.03), having an opportunistic infection (AOR = 1.45, 95 %
CI: 0.58–2.4), more than 3 TB foci in the lungs (AOR = 1.98, 95 % CI: 1.49–3.25), total time of first treatment was more
than 8 months (AOR = 1.39, 95 % CI: 0.65–2.54), adverse effects of anti-TB medication (AOR = 2.39, 95 % CI: 1.40–3.26),
and more than 3 prior episodes of anti-TB treatment (AOR = 1.83, 95 % CI: 1.26–2.80).
Conclusion: The identified risk factors should be given priority in TB control programs. Additionally, there is a
compelling need for better management and control of MDR-TB, particularly through increasing laboratory capacity,
regular screening, enhancing drug sensitivity testing, novel MDR-TB drug regimens, and adherence to medication.
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Background
Tuberculosis (TB), which is an infectious airborne disease,
is a major health problem worldwide. Globally, TB is the
second most lethal disease, next only to AIDS [1, 2]. Add-
itionally, a growing concern is the development of multi
drug resistant (MDR) forms of TB, which have developed
due to partial or incomplete treatments. MDR-TB is de-
fined as disease with mycobacterial strains that are
resistant to two of the most effective and important anti-
TB drugs: isoniazid and rifampin. These two drugs are
considered first-line drugs and are recommended for
the treatment of all individuals with drug-susceptible
TB disease.
In China, 6 % of Mycobacterium tuberculosis isolates
are resistant to isoniazid, and 1 % of isolates are multi-
drug resistant [3]; thus, MDR-TB has become a major
public health problem and an obstacle to global TB con-
trol [4]. Globally, more than 10.5 million incident cases
of TB were estimated to occur in 2010, most of which
occurred in Asia and Africa [5]. The mortality rates due
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to MDR-TB have appeared to increase in leaps and
bounds, and this ominous phenomenon is generally ob-
served in developing and under-developed parts of the
world [6, 7]. Overall, the 27 high burdened countries ac-
count for 85 % of all MDR-TB cases. In light of the ris-
ing numbers of TB cases, the problem of anti-tubercular
drug resistance remains a significant concern [8]. In
China, MDR-TB cases are more difficult and costly to
treat and require appropriate treatment and control
mechanisms [9]. Although TB is one hundred percent
curable, MDR-TB is more difficult to treat than drug
susceptible TB because it requires the use of less effect-
ive second line anti tubercular drugs, which are often as-
sociated with major side effects [10].
Currently, no epidemiological or case control studies
are available in Henan province for MDR-TB. Therefore,
to describe the characteristics and assess the factors that
determine the occurrence of MDR-TB in Henan prov-
ince, we conducted a case control study on MDR-TB be-
tween June 2012 and December 2013.
Methods
Ethical consideration
Ethical clearance (2012HN12254, June 2012-December
2013) was obtained from the medical ethics committee
of the medical association of Henan province and from
each selected health facility. During the study, ethical
clearance was also obtained from the health facilities on
behalf of the study participants to collect secondary data
and to trace the study participants who were not avail-
able at the clinic during the study period. Voluntary
written informed consent was obtained from all of the
participants included in the study.
Study design and study area
This case-control study was conducted from June 2012
to December 2013. The study was conducted in Henan
province, China. Henan province has 18 cities and 89
towns, 342 administrative villages, and an estimated
population of one hundred million; 69.4 % of the inhabi-
tants live in rural areas. This case-control study among
MDR-TB patients was conducted retrospectively.
Study population
For the present study, the MDR-TB cases were selected
from the following five hospitals: the first affiliated hos-
pital of Xinxiang medical college, the Xinxiang city peo-
ple’s hospital, the TB hospital in Henan province, the
Xinxiang city huaxin hospital, and the Xinxiang city sec-
ond people’s hospital. The controls were selected from
the following five community health service centers in
Xinxiang city: the Jian She road community health ser-
vice center, the Yan Dian street community health ser-
vice center, the De Bei street community health service
center, the Xin Zhuang street community health service
center, and the De Nan street community health service
center.
The cases were selected using multistage probability
sampling methods, and the controls were selected by
random sampling from the same five hospitals. The in-
clusion criteria for the cases were as follows: (1) M. tu-
berculosis was detected in the patient’s bacterium
identification test; (2) the strains were resistant to at
least isoniazid and rifampin by drug susceptibility test-
ing, which was routinely performed on isolates of M. tu-
berculosis using the proportion method (minimum
inhibitory concentrations: isoniazid 0.2 mg/ml, rifampin
40 mg/ml, streptomycin 4 mg/ml, ethambutol 2 mg/ml,
kanamycin 30 mg/ml, and ofloxacin 2 mg/ml); (3) a his-
tory of treatment with anti-TB drugs for more than
1 month, i.e., treatment classification in the medical re-
cords was ‘previously treated’, including relapses, treat-
ment after failure, treatment after default, and chronic
patients; (4) the patient was registered between June
2012 and December 2013; (5) the patient was willing to
participate in the study; and (6) complete medical re-
cords were available; (7) the cases of primary MDR (un-
treated patients) were exluded.
The inclusion criteria for the controls were the same
as those for the cases, except that the strains were sensi-
tive to both isoniazid and rifampin by drug susceptibility
testing. The exclusion criterion for the cases and con-
trols was as follows: the patient could not provide cor-
rect information, such as TB patients with mental illness
or alcohol abuse patients.
Drug susceptibility test
Sputum samples were processed using N-acetyl-L-cystei-
nesodium hydroxide and centrifugally concentrated for
acid fast bacilli smear examination and M. tuberculosis
culture. Drug susceptibility testing was performed as
previously [11]. Briefly, the concentrated pellet was sus-
pended in buffer (pH 6.8) and was cultured in liquid
medium (BACTEC MGIT 960, Becton Dickenson Diag-
nostics). A Middlebrook 7H10 agar (Difco), 1 % propor-
tion test of susceptibility to isoniazid 0.2 μg/ml, rifampin
1 μg/ml, streptomycin 2 μg/ml, ethambutol 5 μg/ml,
kanamycin 5 μg/ml, and ofloxacin 4 μg/ml was per-
formed on M. tuberculosis confirmed cultures. Patients
resistant to isoniazid and rifampin (with or without re-
sistance to additional anti-TB drugs) were classified as
MDR-TB infected.
Data collection
A structured questionnaire was used to collect informa-
tion from the study participants. Secondary data were
collected from TB and MDR-TB registers. Patient charts
and the data collection format were used to determine
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and record the patients’ initial TB episode. Day-long
training was provided to the nurses and health officers
involved in the data collection process. The main variables
included in study instrument were sex, age, nationality, re-
ligion, occupation, education degree, marital status,
monthly income of the family (RMB), patient residence,
family size, estimated distance of residence from the
health facility, smoking, alcoholism, knowledge regarding
MDR-TB, means of transportation to reach the health fa-
cility, estimated time to reach the health facility (hrs), so-
cial stigma, previous TB treatment, previous known
contact with an MDR-TB patient, opportunistic infection,
defaulting from treatment, number of TB foci in the lung,
total time of first treatment, adverse effects of anti-TB
medication, and prior episodes of anti-TB treatment.
Data management and analysis
The data were entered using Epidata version 3.1, and the
data analysis was performed using SPSS 16.0 software
(SPSS Inc., Chicago, IL, USA). The data completeness
and consistency were checked by running frequencies of
each variable. Multiple logistic regression models were
used to control the confounding effects of different vari-
ables while assessing the effect of each variable on the
likelihood of MDR-TB occurrence. The odds ratios
(ORs) and 95 % confidence intervals (95 % CIs) were
used to quantify the strength of the association between
potential risk factors and MDR-TB. A p-value of 0.05
was used as the cut-off point for statistical significance.
Results
Socio-demographic characteristics of the study
participants
The analyses of socio-demographic characteristics of
participants (including sex, age, nationality, religion, oc-
cupation, education, marital status, family income, pa-
tient residence and family size) are shown in Table 1.
Factors associated with MDR-TB
There was a very large difference in previous TB treat-
ment history between the cases and controls: 214 (74.36)
cases had previously been treated for TB, whereas only
127 (43.82) controls had a previous TB treatment his-
tory. As a result, previous TB treatment (AOR = 4.51,
95 % CI: 3.55–5.56) was found to be a strong risk factor
for MDR-TB. In addition, this study revealed that the male
sex (AOR = 1.09, 95 % CI: 0.24–1.88), a high school or
lower education degree (AOR = 1.87, 95 % CI: 1.27–2.69),
unemployment (AOR = 1.30, 95 % CI: 0.78–2.52), long
distance of residence from the health facility (AOR = 6.66,
95 % CI: 5.92–7.72), having ever smoked (AOR = 2.07,
95 % CI: 1.66–3.19), poor knowledge regarding MDR TB
(AOR= 2.06, 95 % CI: 1.66–2.92), traveling by foot to
reach the health facility (AOR = 1.85, 95 % CI: 1.12–3.09),
estimated amount of time to reach the health facility was
greater than 3 h (AOR = 1.42, 95 % CI: 0.51–2.35), social
stigma (AOR = 1.17, 95 % CI: 0.27–2.03), having an oppor-
tunistic infection (AOR = 1.45, 95 % CI: 0.58–2.4), more
than 3 TB foci in the lung (AOR = 1.98, 95 % CI: 1.49–
3.25), first treatment lasted more than 8 months (AOR =
1.39, 95 % CI: 0.65–2.54), adverse effects of anti-TB medi-
cation (AOR = 2.39, 95 % CI: 1.40–3.26), and more than 3
Table 1 Socio-demographic distribution of cases and controls,
Henan province, 2013
Variables Case (287) Control (291) Total (578)
n % n % n %
Sex
Female 58 20.21 89 30.58 147 25.43
Male 229 79.79 202 69.42 431 74.57
Age (years)
≤29 39 13.59 29 9.96 68 11.76
30–59 64 22.3 68 23.37 132 22.84
≥60 184 64.11 194 66.67 378 65.4
Nationality
Han Nationality 251 87.34 241 82.75 492 85.12
Other Nationality 36 12.66 50 17.25 86 14.88
Religion
Christian 20 7.12 15 5.32 35 6.05
Muslim 7 2.42 9 2.96 16 2.77
No religion 260 90.46 267 91.72 527 91.18
Occupation
Unemployed 182 63.41 151 51.89 333 57.61
Employed 105 36.59 140 48.11 245 42.39
Education degree
High school or lower 211 73.52 157 53.95 368 63.67
University or higher 76 26.48 134 46.05 210 36.33
Marital status
Married 185 64.57 179 61.39 364 62.98
Single 76 26.48 72 24.83 148 25.61
Divorced 20 6.84 31 10.52 51 8.82
Widowed 6 2.11 9 3.26 15 2.59
Monthly income of the Family (RMB)
≤3000 231 80.44 228 78.35 459 79.41
3000–5000 45 15.57 40 13.89 85 14.71
≥5000 11 3.99 23 7.76 34 5.88
Patient residence
Rural 197 68.49 175 60.18 372 64.36
Urban 90 31.51 116 39.82 206 35.64
Family size
≤3 142 49.32 156 53.74 298 51.56
≥4 145 50.68 135 46.26 280 48.44
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prior episodes of anti-TB treatment (AOR =1.83,
95 % CI: 1.26–2.80) as the most important factors
contributing to the development of MDR-TB in
Henan province in China. However, this study did not
indicate that age, alcoholism, ventilation in room,
having previous known contact with an MDR-TB pa-
tient, or defaulting from treatment were significantly
associated with MDR-TB development (see Table 2).
Discussion
Anti-TB drug resistance is a major public health prob-
lem that threatens progress in TB care and control
worldwide. Essentially, drug resistance arises in areas
with weak TB control programs [12]. TB bacteria can
become resistant to the drugs used for treatment. When
this occurs, treatment is often still possible, but it is
complex, long, challenging, and expensive [10]. Further-
more, a patient who develops active disease with a drug-
resistant TB strain can transmit this form of TB to other
individuals. Drug-resistant TB can occur when the drugs
used to treat TB are not used as prescribed. This may
happen when: a patient misses doses or does not
complete the full course of treatment; a health care pro-
vider prescribes the wrong treatment, wrong dose, or
wrong length of time for taking the drugs; effective
drugs are not available; and the drugs are of poor quality
[7, 13]. Some theoretical studies have suggested that
drug resistance in M. tuberculosis occurs due to genetic
factors, factors related to previous anti-TB treatment,
human immunodeficiency virus (HIV) co-infection and
environment factors [1, 14]. Although there is some evi-
dence to postulate host genetic predisposition as the
basis for the development of MDR-TB, the accumulation
of changes in the genomic content that occur through
gene acquisition and loss is the major underlying event
in the emergence of fit and successful strain variants in
the M. tuberculosis complex. Spontaneous chromosom-
ally borne mutations occurring in M. tuberculosis at a
predictable rate are thought to confer resistance to anti-
TB drugs [15].
Previous studies found that being male was a risk fac-
tor for MDR-TB development. Similarly, studies showed
that the male sex was a risk factor for the development
of MDR-TB [15, 16]. Another study showed that males
have an increased risk for MDR-TB, and being male was
a risk factor for defaulting from anti-TB medication.
Moreover, this study showed that among MDR-TB cases
who were defaulters in their first-line TB treatment,
62.5 % were males [15]. Likewise, our study showed that
males had an increased risk for the development of
MDR-TB. The association between being male and hav-
ing MDR-TB could be because males have a higher ten-
dency to not adhere to anti-TB treatment than females,
thus increasing their risk of developing MDR-TB [17].
Marital status, as one kind of sociodemographic char-
acteristic, is often related to diseases, including TB. In
our study, being single was a risk factor for MDR-TB,
which was in agreement with many other studies that
showed that single persons were more likely to develop
TB [18, 19]. Although there isn’t an identifiable bio-
logical relationship between marital status and TB, single
persons are more likely to lack social support or be in-
volved in high-risk behaviors, such as alcohol consump-
tion or smoking, which potentially leaves them exposed
to higher risks of infection of TB or MDR-TB than those
with other marital statuses.
Like marital status, income levels are also interrelated
with disease and health. Previous studies found that a
low socioeconomic status or poverty were associated
with MDR-TB [20, 21]. In our study, low income was
also a risk factor associated with MDR-TB. Conse-
quently, we infer that it is easy for TB patients in low-
income communities to acquire MDR-TB because there
is a lack of good medical services. With the increase of
acquired MDR-TB patients in low-income communities,
the general population has higher chances of contracting
MDR-TB. This finding also suggests that transmission of
MDR-TB is not extensive in the general population and
still confined to low-income communities.
In this study, we first identify social stigma as risk fac-
tors for MDR-TB in China, with no identifiable risk fac-
tor reported prior to this. It is known that bad habits
potentially increase the risks for MDR-TB. If bad habits
develop into crime leading to social stigma, it might be-
come a risk factor associated with TB. Therefore, our
study provided important evidence that social stigma
was a risk factor for MDR-TB.
Another study assessing the risk factors associated
with MDR-TB revealed that previous treatment was the
strongest determinant of MDR-TB and that the pooled
risk of MDR-TB was more than 5 times higher in previ-
ously treated cases than in never-treated cases [22]. As
found in many other studies, a history of anti-TB treat-
ment has been consistently associated with the risk of
MDR-TB. Previously treated patients often constitute a
very heterogeneous group including those who experi-
ence relapse after receiving successful treatment, those
who return after default, and those who start receiving a
re-treatment regimen after having experienced previous
treatment failure [9]. Our study is consistent with former
reports that revealed the importance of previous treat-
ment history in the risk of drug resistance.
The principal patient related factor that predicts the
occurrence of MDR-TB is drug non adherence; thus, the
category II regimen was blamed for increasing the
chances of developing MDR-TB. MDR-TB develops due
to errors in TB management such as the use of a single
drug to treat TB, the addition of a single drug to a failing
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Table 2 Determinants of multidrug-resistant tuberculosis from the logistic regression model, Henan province, China, 2013
Variable Case (n = 287) Control (n = 291) COR (95 % CI) AOR (95 % CI)a P Value
Sex
Male 229 (79.79) 202 (69.42) 0.57 (1.43–2.76) 1.09 (0.24–1.88) 0.006
Female 58 (20.21) 89 (30.58) 1
Age (years)
≤29 39 (13.35) 29 (10.14) 1.43 (0.53–2.81) 2.08 (1.11–2.94) 0.401
30–59 64 (22.43) 68 (22.85) 0.99 (1.18–2.71) 1.48 (0.62–2.26) 0.642
≥60 184 (64.22) 194 (67.01) 1
Education degree
High school or lower 211 (73.55) 157 (54.16) 2.37 (1.49–4.23) 1.87 (1.27–2.69) 0.000
University or higher 76 (26.45) 134 (45.84) 1
Occupation
Unemployed 182 (63.18) 151 (51.76) 1.61 (0.55–4.05) 1.30 (0.78–2.52) 0.007
Employed 105 (36.81) 140 (48.24) 1
Estimated distance of residence from the health facility
Long 236 (82.19) 126 (43.52) 6.06 (5.04–7.85) 6.66 (5.92–7.72) 0.000
Short 51 (17.81) 165 (56.48) 1
Smoking
Ever 212 (73.58) 143 (49.38) 2.93 (1.98–4.36) 2.07 (1.66–3.19) 0.000
Never 75 (26.42) 148 (50.62) 1
Alcoholism
Yes 113 (39.16) 125 (43.25) 0.86 (0.37–2.03) 0.43 (0.37–1.42) 0.429
No 174 (60.84) 166 (56.75) 1
Ventilation in Room
Yes 139 (48.37) 146 (50.29) 0.93 (0.62–1.93) 1.55 (0.65–2.52) 0.738
No 148 (51.63) 145 (49.71) 1
Knowledge on MDR-TB
Poor 211 (73.48) 143 (49.42) 2.87 (2.46–3.88) 2.06 (1.66–2.92) 0.000
Good 76 (26.52) 148 (50.58) 1 1
Means of transportation to reach the health facility
On foot 175 (61.29) 143 (49.46) 1.62 (1.38–3.43) 1.85 (1.12–3.09) 0.006
By car 112 (38.71) 148 (50.54) 1 1
Estimated time it takes to reach the health facility (hrs)
>3 142 (49.67) 152 (52.46) 0.9 (0.44–2.54) 1.42 (0.51–2.35) 0.000
≤3 145 (50.33) 139 (47.54) 1 1
Social Stigma
Yes 183 (63.67) 140 (48.27) 1.9 (1.47–4.12) 1.17 (0.27–2.03) 0.000
No 104 (36.33) 151 (51.73) 1 1
Previous TB treatment
Yes 214 (74.36) 127 (43.82) 3.79 (3.36–5.35) 4.51 (3.55–5.56) 0.000
No 73 (25.64) 164 (56.18) 1 1
Having previous known contact with an MDR-TB patient
Yes 170 (59.16) 122 (42.09) 2.01 (1.77–3.65) 1.37 (0.61–2.16) 0.562
No 117 (40.84) 169 (57.91) 1 1
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regimen, the failure to identify preexisting resistance, the
initiation of an inadequate regimen using first line anti
tubercular drugs and variations in the bioavailability of
anti-TB drugs to predispose the patient to the develop-
ment of MDR-TB [23]. A shortage of drugs has been
one of the most common reasons for the inadequacy of
the initial anti-TB regimen, particularly in resource poor
settings [24]. Other major issues significantly contribut-
ing to the higher complexity of the treatment of MDR-
TB is the increased cost of treatment.
Certainly, inadequate treatment adherence also in-
creases the risk of developing MDR-TB. Non-adherence
to prescribed treatment is often underestimated by the
physician and is difficult to predict. Certain factors such
as psychiatric illness, alcoholism, drug addiction, and
poverty can predict non-adherence to treatment [25].
Poor compliance with treatment is also an important
factor in the development of acquired drug resistance
[26]. MDR-TB requires a two- to four-fold longer period
of treatment compared with drug susceptible TB [15].
Most of the problems from which drug resistance origi-
nates are related to length of treatment. The longer time
that is required to treat MDR-TB clearly implies an
additional risk of poor treatment adherence and conse-
quently of treatment failure [1, 13].
Other factors also play important roles in the develop-
ment of MDR-TB, such as poor administrative control on
the purchase and distribution of the drugs with no proper
mechanisms for quality control and bioavailability tests
[27]. TB control programs implemented in the past have
also partially contributed to the development of drug re-
sistance due to poor follow up and infrastructure.
Therefore, the following recommendations should be
considered: health professionals ought to enhance their
efforts in controlling MDR-TB; public awareness regard-
ing MDR-TB should be increased; the effectiveness of
category II regimens in treating TB patients requires fur-
ther study; better management and control of TB, par-
ticularly drug resistant TB, should be conducted by
experienced and qualified doctors; access to standard
microbiology laboratories is necessary; understanding
the co-morbidity of HIV and TB is necessary; new anti-
TB drug regimens and better diagnostic tests should be
created; the laboratory capacity for drug sensitivity tests
should be increased as much as possible; international
standards should be created for second line drug-
susceptibility testing; new antitubercular molecules and
vaccines should be invented, and we must determine the
real magnitude of MDR-TB. These recommendations
are some of the important issues that must be addressed
for effective prevention, control and management of
MDR-TB. The strengths of the current study are that
the cases and controls had a better likelihood of coming
from similar backgrounds and had most likely received
the same services. All of the cases that fulfilled the eligi-
bility criteria who were available during the study period
and willing to respond were included in the study. This
was helpful in decreasing sampling error.
Table 2 Determinants of multidrug-resistant tuberculosis from the logistic regression model, Henan province, China, 2013
(Continued)
Having an opportunistic infection
Yes 185 (64.37) 147 (50.68) 1.78 (1.28–3.55) 1.45 (0.58–2.4) 0.001
No 102 (35.63) 144 (49.32) 1 1
Defaulting from treatment
Yes 145 (50.18) 160 (55.28) 0.84 (0.09–3.04) 0.28 (0.38–1.18) 0.322
No 142 (49.82) 131 (44.72) 1 1
Number of TB foci in the lung
>3 172 (59.83) 143 (49.27) 1.55 (1.13–3.72) 1.98 (1.49–3.25) 0.012
≤3 115 (40.17) 148 (50.73) 1 1
Total length of first treatment
≥8 months 157 (54.38) 120 (41.28) 1.72 (1.02–3.49) 1.39 (0.65–2.54) 0.001
<8 months 130 (45.62) 171 (58.72) 1 1
Adverse effects of anti-TB medication
Yes 177 (61.47) 148 (50.87) 1.55 (1.26–3.14) 2.39 (1.40–3.26) 0.011
No 110 (38.53) 143 (49.13) 1 1
Prior episodes of anti-TB treatment
≥3 times 176 (61.26) 152 (52.38) 1.45 (0.7–3.16) 1.83 (1.26–2.80) 0.034
<3 times 111 (38.74) 139 (47.62) 1 1
Note. aAdjusted for age, sex
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However, the current study is not without limitations.
Recall bias could be considered a potential challenge be-
cause some of the information was based on the recall
of the study participants. Furthermore, there is also a
potential bias in estimating drug resistance in patients.
Although we reviewed the medical records and screened
the case notification system to check for previous epi-
sodes of TB, we could not exclude the possibility of mis-
classification. Moreover, because of the retrospective
nature of our study, it was not possible to demonstrate a
causal relationship between the variables. Additionally,
missing data may have affected our results. Nevertheless,
our findings are similar to previous reports. Thus, we
believe that the effect of missing values was not import-
ant in our analysis, and we have adjusted our results ac-
cording to some confounding factors (sex and age).
Although our primary interest was to identify risk fac-
tors that increased the risk of developing MDR-TB asso-
ciated with the occurrence of anti-TB adverse drug
reactions, these findings need to be corroborated with
multi-center case-control studies to bring out nationally
relevant risk factors for MDR-TB.
Conclusion
In conclusion, previous TB treatment, male sex, low
education, unemployment, smoking, poor knowledge of
MDR TB, social stigma, adverse effects of anti-TB medi-
cation, prior episodes of anti-TB treatment, being far
from the health facility, traveling to the health facility on
foot, and more TB foci were shown to increase the risk
for MDR-TB. The identified risk factors should be given
priority in effective TB control programs under the
health bureau of Henan province to control MDR-TB.
Evaluating the current scenario, there is a compelling
and urgent need for increasing public awareness, effect-
ive new anti-TB drug regimens, standard microbiology
laboratories, better diagnostic tests, enhancing drug sen-
sitivity tests, inventing new antitubercular molecules and
vaccines, regular screening, and better management and
control of MDR-TB; these actions will be stepping
stones towards controlling this disease, which is becom-
ing deadlier by the day.
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